In an interview with PharmaBoardroom, Dr. David Chang, CEO of TBMC, shares his vision to build a leading cell and gene therapy CDMO in Taiwan.
Drawing on over three decades of industry experience, he highlights Taiwan’s unique strengths—including technical talent, cost efficiency, and strategic positioning—and its growing role in advancing next-generation biologics manufacturing.
